a hrefhttps:www.fiercepharma.compharmaits-bms-vs-celgene-investors-again-after-us-appeals-court-ruling hreflangenIts BMS vs. Celgene investors once more after US appeals court revives lawsuita

A U.S. appeals court has revived a lawsuit filed by Celgene shareholders that accuses Bristol Myers Squibb of slow-playing the approval of blood cancer drug Breyanzi to avoid paying out a more than 6 billion contingent value right.